Previous 10 | Next 10 |
The biotech indices have fallen considerably. Many biotechs are trading with negative enterprise values despite unprecedented innovation in the biotech industry. I-Mab is headed for commercialization with enough cash to carry then into 2025 with multiple products hitting the ...
The S&P 500 is now officially in a bear market. 73% of all stocks are now down 20% or more, with the median stock down by -29.4%. The causes of today's rout were an inflation hangover and recession fears. The next shoe to drop could be a 75 bp hike in the Fed Funds rate. T...
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 43 rd...
The 2022 American Society of Clinical Oncology Annual Meeting that begins June 3 is perhaps is the most eagerly anticipated medical meeting of the year. Thousands of abstracts and studies will be presented from pharma and biotech companies large and small. Some of the results are ea...
The following slide deck was published by Arcus Biosciences, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Arcus Biosciences, Inc. 2022 Q1 - Results - Earnings Call Presentation
The Chief Medical Officer of Arcus Biosciences (NYSE:RCUS) Kartik Krishnan has left the clinical-stage biotech to pursue another opportunity elsewhere ahead of a major readout on its anti-TIGIT program, Endpoints News reported on Friday. The move “wasn’t abrupt” and the c...
Wedbush analyst Robert Driscoll lowered the firm's price target on Arcus Biosciences (RCUS -28.8%) to $42 from $67 and keeps an Outperform rating on the shares. The analyst reported that the Phase 3 SKYSCRAPER-01 study failed to meet the co-primary endpoint of PFS, which he believes casts a s...
Gainers: Trecora Resources (TREC) +27%. Golden Matrix Group (GMGI) +24%. Charge Enterprises (CRGE) +21%. Inspired Entertainment (INSE) +20%. Celsius Holdings (CELH) +20%. QualTek Services (QTEK) +18%. Blue Water Vaccines (BWV) +18%. Grocery Outlet Holding (GO) +17%. H&R Block (HRB) +17%. ...
Gainers: Blue Water Vaccines (BWV) +18%. Oscar Health (OSCR) +13%. Veru (VERU) +10%. Zai Lab (ZLAB) +8%. Better Therapeutics (BTTX) +6%. Losers: Inovio Pharmaceuticals (INO) -32%. iTeos Therapeutics (ITOS) -32%. Arcus Biosciences (RCUS) -28%. Akand...
A group of pharma companies focused on ant-TIGIT class of drugs are trading sharply lower in the pre-market Wednesday after French pharma giant Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced that a similar treatment failed in a late-stage trial for non-small cell lung cancer (NSCLC). The global ...
News, Short Squeeze, Breakout and More Instantly...
Arcus Biosciences Inc. Company Name:
RCUS Stock Symbol:
NYSE Market:
Arcus Biosciences Inc. Website:
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Thursday, August 8 th , 2024 at 2 PM...
Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), an investigational small molecule CD73 inhibitor, in Japan and certain oth...
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing di...